News

Chugai’s DONQ52, a Multispecific Antibody under Development for Celiac Disease, Non-Clinical Research Results Published in Nature Communications

Anti-CD20 Monoclonal Antibody Rituxan^® Approved for Suppression and Treatment of Antibody-mediated Rejection in Organ Transplantation

Decision to Invest over 20 Billion Yen in Bio Drug Substance Manufacturing Building “UK3” to Expand its Production Capacity and towards Realizing Halogenated Hydrocarbon-Free

Chugai Venture Fund Starts Investment Activities in Drug Discovery Start-Ups to Accelerate Innovation

Chugai Files for Additional Indication of Alecensa for Postoperative Adjuvant Therapy for ALK Fusion Gene-Positive Non-Small Cell Lung Cancer

Chugai Received Second Rating in Pharmaceutical Sector in the “DJSI World,” a Global ESG Investment Index

New Data Reinforce the Benefit of Early Preventative Treatment with Chugai’s Hemlibra for Babies with Severe Hemophilia A

Roche Announces Significant Overall Survival Benefit for Kadcyla in HER2-Positive Early-Stage Breast Cancer

Chugai Launches Phesgo Subcutaneous Combination for the Treatment of HER2-Positive Breast and Colorectal Cancer

Organizational and Personnel Changes

Chugai Receives the Best IR Award, the Greatest IR Improvement Premium Companies, and the Best Continual IR Efforts Premium Companies

The Launch of Chugai’s New TV Commercial Featuring Tori Matsuzaka “Innovation Lab / AI-leveraging Drug Discovery”

Non-Clinical Research Results of Chugai’s NXT007 Published in Journal of Thrombosis and Haemostasis

Transfer and Future Marketing of Anti-Cancer Agent “Xeloda^® Tablets 300” in Japan

Roche Announces Outcomes for EMBARK Study of Elevidys in Duchenne Muscular Dystrophy

Galderma Announces Nemolizumab Data Published in the New England Journal of Medicine

Chugai Announces 2023 3^rd Quarter Results

Notice of the Settlement of Patent Infringement Litigation in the U.S.

Tecentriq plus Chemotherapy and Avastin Reduced the Risk of Disease Worsening or Death in Phase III study in People with Extensive-stage Small Cell Lung Cancer

Chugai’s Alecensa Reduces the Risk of Disease Recurrence or Death by 76% in People with ALK-Positive Early-Stage Non-Small Cell Lung Cancer

Contribution of Para-transit Vehicles to Welfare Services

F. Hoffmann-La Roche Announces Third Quarter Sales 2023

Roche Announces Updates on Alecensa for Adjuvant Therapy in ALK-Positive Early-Stage Non-Small Cell Lung Cancer

Galderma Announces Updates on Nemolizumab Development

Roche Announces Updates on Retinal Vein Occlusion (RVO) for Vabysmo

Chugai’s Enspryng Launched in Taiwan as First Indication for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Chugai Obtains Regulatory Approval for Phesgo, the Fixed-Dose Subcutaneous Combination of Perjeta and Herceptin for HER2-Positive Breast and Colorectal Cancer

Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan

FDA Accepts Application for Chugai’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition

Chugai’s Alecensa Delivers Positive Phase III Results for People with ALK-Positive Early-Stage Lung Cancer

Anti-CD20 Monoclonal Antibody Rituxan^® Approved for Lupus Nephritis that has Not Responded Sufficiently to Existing Therapies

Personnel Change

Chugai Announces 2023 Half Year Results

F. Hoffmann-La Roche Announces Half Year Results 2023

Chugai, OMRON, and OMRON SINIC X Begin Testing of Flexible and Highly Human-Friendly Lab Automation System at Chugai Life Science Park Yokohama

Chugai Files Patent Infringement Lawsuit against Biogen MA Inc. and Bio-Thera Solutions, Ltd. in the U.S.

Chugai’s Hemlibra Launched for Congenital Hemophilia A without Inhibitors in Taiwan

Chugai Establishes Corporate Venture Capital to Accelerate Innovation Opportunities with Drug Discovery Start-ups

New Data from the Japanese Phase III Clinical Trial of Hemlibra for Acquired Hemophilia A (AGEHA Study) Presented at ISTH

Chugai Files New Drug Application in Japan for Crovalimab for Paroxysmal Nocturnal Hemoglobinuria

Personnel Change

New Data Presented at EHA Show Chugai’s Subcutaneously Administered Crovalimab Achieved Disease Control and was Well-Tolerated in People with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Chugai Selected as “DX Platinum Companies 2023-2025” in Digital Transformation Stocks (DX Stocks) 2023

New Investment of Over 50 Billion Yen in Bio Manufacturing Facilities to Strengthen the Production Base to Support the Rapid Launch of In-House Projects

Personnel Changes

Chugai Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Novartis’ MET Inhibitor, Capmatinib, Which Is Approved for MET Exon 14 Skipping Mutation-Positive Advanced and/or Recurrent Unresectable Non-Small Cell Lung Cancer

Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Chugai Announces 2023 1^st Quarter Results

Implementation and Results of Early Retirement Incentive Program

Organizational and Personnel Changes

Chugai Files for Additional Indication of Vabysmo for Macular Edema Associated with Retinal Vein Occlusion in Japan

F. Hoffmann-La Roche Announces First Quarter Sales 2023

Chugai’s Actemra Approved in Taiwan for the treatment of COVID-19 in Hospitalized Adults

Chugai and TWOCELLS Announce the Decision of the Termination of License Agreement on Investigational Regenerative Cellular Medicine for Knee Chondrogenesis (gMSC^®1)

Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Chugai Receives Forerunner Designation for Enspryng in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) and Autoimmune Encephalitis (AIE)

Galderma Announces Updates on Nemolizumab Development

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

Chugai Files for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Treatment in Japan

Chugai’s Anti-IL-8 Recycling Antibody AMY109, Improves Inflammation and Fibrosis in Endometriosis in an Industry-Government-Academia Non-Clinical Study Published in Science Translational Medicine

Support for the Earthquake in Turkey and Syria

Chugai Announces Positive Data from Global Phase III Program for Crovalimab in PNH, a Rare Life-Threatening Blood Condition

Personnel Changes

Chugai Announces 2022 Full Year Results and Forecasts for 2023

Notice of Distribution of Retained Earnings

Notice Regarding the Difference of Individual Financial Results as Compared to Actual Results for the Previous Year

F. Hoffmann-La Roche Announces Financial Results for fiscal 2022

Chugai’s Hemlibra Approved by the European Commission to Treat People with Moderate Hemophilia A